The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma.

Scottish swimmer Archie Goodburn was diagnosed with oligodendrogliomas at just 23 Here’s all you need to know about the rare ...

While surgery using 5-aminolevulinic acid improves total resection rates in high-grade glioma, the best outcomes are seen ...

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceuticals.

Gliomas are among the most aggressive brain tumors, with glioblastoma offering a median survival of 12 to 15 months. Despite advances in surgical, ...

He is now at 82 months from original diagnosis. “We were surprised to discover that KMT could work synergistically with the IDH1 mutation to simultaneously target the two major metabolic pathways ...